Trinity Biotech plc (NASDAQ:TRIB) Q1 2022 Earnings Conference Call June 30, 2022 11:00 AM ET Company Participants Joe Diaz - Lytham Partners, IR Ronan OÂ'Caoimh - Chairman and Chief Executive Officer John Gillard - Chief Financial Officer and Director Conference Call Participants Jim Sidoti - Sidoti & Co Operator Good day, and welcome to the Trinity Biotech First Quarter Financial Results Conference Call. All participants will be in a listen-only mode. [Operator Instructions] Please note this event is being ...

SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT ...

Exhibit 99.1 Press Release dated April 11, 2022 Contact: Trinity Biotech plc Lytham Partners, LLC John Gillard Joe Diaz (353)-1-2769800 (1)-602-889-9700 E-mail: investorrelations@trinitybiotech.com Trinity Biotech Announces Quarter 4 and Fiscal Year 2021 Financial Results DUBLIN, Ireland (April 11, 2022)…. Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended Decembe ...

Exhibit 99.1 September 30, 2021 Contact: Trinity Biotech plc Lytham Partners, LLC John Gillard Joe Diaz (353)-1-2769800 (1)-602-889-9700 E-mail: investorrelations@trinitybiotech.com Trinity Biotech Announces Results of AGM Dublin, Ireland (September 30, 2021)…. Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results of the Annual General Meeting (AGM). AGM Results On September 29, 2021 Trin ...

Trinity Biotech plc (NASDAQ:TRIB) Q2 2021 Earnings Conference Call September 9, 2021 11:00 AM ET Company Participants Joe Diaz - Lytham Partners Ronan OÂ'Caoimh - Chairman and Chief Executive Officer John Gillard - Chief Financial Officer and Director Conference Call Participants Jim Sidoti - Sidoti & Co Paul Nouri - Noble Equity Funds Operator Good morning, everyone. And welcome to the Trinity Biotech Q2 2021 Financial Results Conference Call. All participants will be in a listen-only mode. [Operator Instr ...

Trinity Biotech plc (NASDAQ:TRIB) Q1 2021 Results Conference Call May 25, 2021 11:00 AM ET Company Participants Joe Diaz - Lytham Partners Ronan OâCaoimh - CEO John Gillard - CFO Conference Call Participants Paul Nouri - Noble Equity Funds Jim Sidoti - Sidoti & Co Operator Good day, and welcome to the Trinity Biotech First Quarter 2021 Financial Results Conference Call. All participants will be in a listen-only mode. [Operator Instructions] After todayâs presentation, there will be an opportunity to ask que ...

SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT ...

Trinity Biotech plc (NASDAQ:TRIB) Q4 2020 Results Conference Call March 26, 2021 11:00 AM ET Company Participants Ronan O’Caoimh - CEO John Gillard - CFO Conference Call Participants Jim Sidoti - Sidoti & Company Operator Good day, and welcome to the Trinity Biotech Q4 and Fiscal Year 2020 Financial Results Conference Call. All participants will be in a listen-only mode. [Operator Instructions] After today’s presentation, there will be an opportunity to ask questions. [Operator instructions] Please note, th ...

Financial Data and Key Metrics Changes - Revenues increased from $24.6 million to $32 million, representing a growth of over 30% compared to the same quarter last year [5] - Gross margin improved from 41% to 52.4%, driven by increased revenues and the spreading of fixed costs over a wider base [6] - Operating profit rose from nearly $1.3 million to close to $9.1 million, attributed to higher revenues, improved gross margin, and lower indirect costs [9] - Profit after tax for the quarter was over $7.3 million compared to close to breakeven last year, resulting in an EPS of $0.35 [11] Business Line Data and Key Metrics Changes - Point-of-care revenues decreased by 47% to $2.1 million, while Clinical Laboratory revenues increased by 45% to $30 million [20] - The decline in point-of-care revenues was attributed to the impact of COVID-19 and an unusually high quarter in Q3 2019 [20] - Clinical Laboratory revenues did not fully return to pre-COVID-19 levels, particularly in the diabetes business, which saw slow instrument placements [21] Market Data and Key Metrics Changes - Strong sales of COVID-19 related products significantly boosted revenues, including the COVID-19 IgG ELISA antibody test and FDA-approved PCR viral transport media products [22][26] - The company filed for emergency use authorization for its COVID-19 IgG ELISA antibody test and expects to obtain a CE Mark for the product soon [22][23] Company Strategy and Development Direction - The company is focusing on expanding its COVID-19 testing capabilities and expects antibody testing to become more prevalent with the onset of vaccinations [24][36] - Development of a rapid point-of-care COVID-19 test is underway, with expectations to file for emergency use authorization in February [25] - The company is also working on the approval of its HIV trial screen in Africa, with expectations for market entry by mid-2021 [39] Management's Comments on Operating Environment and Future Outlook - Management expressed uncertainty regarding future revenues due to the unpredictable nature of COVID-19 and its impact on traditional business [36] - There is confidence in a strong fourth quarter, but management refrained from providing specific guidance due to ongoing uncertainties [56] Other Important Information - Total indirect costs fell from $8.8 million to $7.7 million, a reduction of over 12% [9] - Cash generation from operations for the quarter was just over $7.2 million, impacted by working capital outflows [15] - The company’s cash balances increased by $4.3 million for the quarter, bringing total cash to just under $20 million [16] Q&A Session Summary Question: Revenue generation from COVID-related products - Management indicated that COVID-related revenues were approximately $12 million to $13 million for the quarter, with expectations for continued revenue generation [34][36] Question: Antibody testing necessity post-vaccination - Management noted that while blanket vaccinations may be recommended, individuals may still seek antibody testing to confirm immunity [38] Question: Update on HIV trial screen approval - Management reported that clinical trials for the HIV trial screen have been stalled due to COVID-19, with expectations for submission to WHO by mid-2021 [39] Question: COVID sales distribution - COVID-related sales are primarily in the U.S. but also distributed globally [42] Question: PCR testing in the lab - Management confirmed that PCR testing is expected to commence soon, pending state authorization, with potential annual revenues of $2 million to $4 million [54][56] Question: Instrument placements in Brazil - Management stated that instrument placements in Brazil have effectively stopped due to currency issues [50]

Trinity Biotech plc (NASDAQ:TRIB) Q2 2020 Earnings Conference Call August 25, 2020 11:00 AM ET Company Participants Kevin Tansley - CFO Ronan O'Caoimh - Chairman & CEO Conference Call Participants Jim Sidoti - Sidoti & Company Paul Nouri - Noble Equity Jim Sidoti - Sidoti & Company William Lapp - Private Investor Sam Roboski - SER Asset Management Operator Good day, and welcome to the Trinity Biotech Second Quarter Financial Results Conference Call. All participants are in a listen-only mode. [Operator Inst ...